cgp 12177 has been researched along with rolipram in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernandez, J; Kaumann, AJ; Vargas, ML | 1 |
| Kaumann, A; Molenaar, P; Semmler, AB | 1 |
| Galindo-Tovar, A; Kaumann, AJ; Vargas, ML | 1 |
3 other study(ies) available for cgp 12177 and rolipram
| Article | Year |
|---|---|
Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-1 Receptor Agonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Heart Ventricles; In Vitro Techniques; Male; Myocardial Contraction; Myocardium; Norepinephrine; Propanolamines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Stimulation, Chemical; Ventricular Function | 2006 |
The effects of both noradrenaline and CGP12177, mediated through human beta1 -adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Aged; Animals; Atrial Appendage; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Synergism; Female; Humans; Isometric Contraction; Isoproterenol; Male; Middle Aged; Norepinephrine; Phosphodiesterase Inhibitors; Propanolamines; Quinolones; Receptors, Adrenergic, beta-1; Rolipram; Signal Transduction | 2007 |
Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Animals; Arrhythmia, Sinus; Atrial Function, Left; Atrial Function, Right; Bradycardia; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Partial Agonism; Female; Heart Atria; Heart Rate; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Propanolamines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Stimulation, Chemical; Tachycardia | 2009 |